EIKNEikon TherapeuticsSigning up patients
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Advanced Solid Tumors · MSI-H or dMMR Advanced Solid Tumors · MSI-H/dMMR Gastric Cancer · MSI-H/dMMR Colorectal Cancer · MSI-H/dMMR Gastroesophageal-junction Cancer · Endometrial Cancer · Mismatch Repair Deficient or MSI-High Solid Tumors
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 160 (planned)
- Started
- Jan 20, 2026
- Main results expected
- Mar 2029
- Fully finished
- Mar 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose-Limiting Toxicity (DLT) - Part 1
Measured over: 21 Days
Adverse Events (AEs) - Part 1 and Part 2
Measured over: From the time of first dose of study medication through 30 days following cessation of study treatment.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07262619 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC